PT2145627E - Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais - Google Patents
Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais Download PDFInfo
- Publication number
- PT2145627E PT2145627E PT91734954T PT09173495T PT2145627E PT 2145627 E PT2145627 E PT 2145627E PT 91734954 T PT91734954 T PT 91734954T PT 09173495 T PT09173495 T PT 09173495T PT 2145627 E PT2145627 E PT 2145627E
- Authority
- PT
- Portugal
- Prior art keywords
- choline
- uridine
- treatment
- mood
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9500298P | 1998-07-31 | 1998-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2145627E true PT2145627E (pt) | 2014-07-24 |
Family
ID=22248474
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT100756618T PT2329829E (pt) | 1998-07-31 | 1999-07-30 | Utilização de uridina em combinação com colina para o tratamento de disfunções neurológicas |
PT91734954T PT2145627E (pt) | 1998-07-31 | 1999-07-30 | Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais |
PT99937631T PT1140104E (pt) | 1998-07-31 | 1999-07-30 | Tratamento da doença de alzheimer, in vivo, por aumento dos níveis de citidina |
PT100756600T PT2322187E (pt) | 1998-07-31 | 1999-07-30 | Utilização de uridina em combinação com colina para o tratamento de disfunções de memória |
PT07116909T PT1870103E (pt) | 1998-07-31 | 1999-07-30 | Utilização de uridina em combinação com colina para o tratamento de perturbações da memória |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT100756618T PT2329829E (pt) | 1998-07-31 | 1999-07-30 | Utilização de uridina em combinação com colina para o tratamento de disfunções neurológicas |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99937631T PT1140104E (pt) | 1998-07-31 | 1999-07-30 | Tratamento da doença de alzheimer, in vivo, por aumento dos níveis de citidina |
PT100756600T PT2322187E (pt) | 1998-07-31 | 1999-07-30 | Utilização de uridina em combinação com colina para o tratamento de disfunções de memória |
PT07116909T PT1870103E (pt) | 1998-07-31 | 1999-07-30 | Utilização de uridina em combinação com colina para o tratamento de perturbações da memória |
Country Status (11)
Country | Link |
---|---|
US (1) | US6989376B2 (pt) |
EP (5) | EP1140104B1 (pt) |
JP (1) | JP2003517437A (pt) |
AT (2) | ATE446097T1 (pt) |
CA (1) | CA2339008C (pt) |
CY (1) | CY1110570T1 (pt) |
DE (2) | DE69937198T2 (pt) |
DK (5) | DK2329829T3 (pt) |
ES (5) | ES2332669T3 (pt) |
PT (5) | PT2329829E (pt) |
WO (1) | WO2000006174A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
US8314064B2 (en) * | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
US20060069061A1 (en) * | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
US7807654B2 (en) | 1998-08-31 | 2010-10-05 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US7915233B1 (en) | 1998-08-31 | 2011-03-29 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
US6727231B1 (en) * | 2000-10-12 | 2004-04-27 | Repligen Corporation | Uridine therapy for patients with elevated purine levels |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
KR20050044890A (ko) * | 2002-07-11 | 2005-05-13 | 야마사 쇼유 가부시키가이샤 | 약제 유발성 신경장해용 의약 조성물 |
CN100430066C (zh) | 2002-11-08 | 2008-11-05 | 麦克莱恩医院 | 用于烟草依赖性和戒断治疗的化合物 |
WO2004058160A2 (en) * | 2002-12-20 | 2004-07-15 | The Mclean Hospital Corporation | Compounds for the normalization of the sleep/wake cycle |
US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
JP2007508315A (ja) * | 2003-10-08 | 2007-04-05 | ザ マクレーン ホスピタル コーポレーション | ω−3脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法 |
JP5523669B2 (ja) * | 2004-05-13 | 2014-06-18 | マサチューセッツ インスティテュート オブ テクノロジー | ドーパミン放出に対するウリジンの効果 |
WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
EP1765364A4 (en) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER |
EP1784199A4 (en) | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION |
CN102600199A (zh) * | 2004-09-15 | 2012-07-25 | 麻省理工学院 | 含有尿苷的组合物及使用其的方法 |
AU2011253660B2 (en) * | 2004-09-15 | 2013-12-19 | Massachusetts Institute Of Technology | Compositions containing uridine, and methods utilizing same |
JP5566603B2 (ja) * | 2005-05-23 | 2014-08-06 | マサチューセッツ インスティテュート オブ テクノロジー | Pufaを含有する組成物及びそれを使用した方法 |
AU2012203650B2 (en) * | 2005-05-23 | 2014-09-18 | Massachusetts Institute Of Technology | Compositions containing PUFA and methods of use thereof |
EP1938824B1 (en) * | 2005-09-22 | 2011-11-30 | Snow Brand Milk Products Co., Ltd. | Medicine, food and drink or feed containing sphingomyelin |
WO2007059762A1 (de) * | 2005-11-25 | 2007-05-31 | Gisela Susilo | Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid |
DK1800675T3 (da) | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
WO2008001495A1 (fr) | 2006-06-27 | 2008-01-03 | Yamasa Corporation | Agent contre les contraintes psychosociales |
US7972633B2 (en) * | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
WO2009059306A1 (en) * | 2007-11-02 | 2009-05-07 | Massachusetts Institute Of Technology | Uridine dietary supplementation compliance methods and use thereof |
US20110160158A1 (en) * | 2008-06-12 | 2011-06-30 | Repligen Corporation | Methods of treatment of bipolar disorder |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
JP6162125B2 (ja) | 2011-09-30 | 2017-07-12 | タフツ・ユニバーシティ | 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法 |
WO2013066152A1 (en) | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
WO2014027882A1 (en) | 2012-08-13 | 2014-02-20 | N.V. Nutricia | Product and method for supporting uridine homeostasis |
JP6523958B2 (ja) | 2012-09-28 | 2019-06-05 | タフツ・ユニバーシティ | ウリジン二リン酸誘導体、プロドラッグ、組成物およびそれらの使用 |
SI2968385T1 (sl) | 2013-03-13 | 2018-10-30 | Tufts University | Uridin nukleozid derivati, sestavki in metode uporabe |
US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
WO2015115885A1 (en) * | 2014-01-31 | 2015-08-06 | N.V. Nutricia | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly |
WO2016053085A1 (en) * | 2014-09-30 | 2016-04-07 | N.V. Nutricia | Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders |
WO2016072842A1 (en) * | 2014-11-05 | 2016-05-12 | N.V. Nutricia | Method for preventing, reducing the risk of, or treating behavioral frontotemporal dementia |
WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
WO2017176109A1 (en) | 2016-04-04 | 2017-10-12 | N.V. Nutricia | Method for reducing or preventing global developmental delay in children |
BR112020013342A2 (pt) * | 2018-02-01 | 2020-12-01 | Wellstat Therapeutics Corporation | composições e dispositivos para fornecimento sistêmico de uridina |
CN114990176A (zh) * | 2022-05-26 | 2022-09-02 | 宁夏华吉生物有限公司 | 一种生产尿嘧啶核苷的方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2508474A1 (de) * | 1975-02-27 | 1976-09-02 | Boehringer Mannheim Gmbh | Infusions- und spuelfluessigkeiten zur behandlung von hirnoedemen |
DE2629845A1 (de) * | 1976-07-02 | 1978-01-05 | Geb Graze Erika Graze | Infusions- bzw. injektionsloesungen bzw. waessrige konzentrate zu deren bereitung zur therapeutischen restituion des zellulaeren energiestoffwechsels und der koerpereigenen regelfunktion |
US4221784A (en) * | 1979-04-05 | 1980-09-09 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering lecithin |
IT1178044B (it) * | 1984-10-09 | 1987-09-03 | Polifarma Spa | Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina |
US4609647A (en) * | 1985-05-28 | 1986-09-02 | Massachusetts Institute Of Technology | Cytidyl diphosphocholine-drug composition and process |
ES2007350A6 (es) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion. |
JP2894610B2 (ja) * | 1987-10-28 | 1999-05-24 | プロ−ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
IT1219667B (it) * | 1988-06-21 | 1990-05-24 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico |
RU2003332C1 (ru) * | 1989-06-09 | 1993-11-30 | Борис Витальевич Страдомский | Средство дл лечени депрессий |
JPH0722495B2 (ja) * | 1990-01-30 | 1995-03-15 | 美穂 田中 | クロレラ含有油脂食品 |
US5141943A (en) | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
US5567689A (en) | 1993-08-13 | 1996-10-22 | The Uab Research Foundation | Methods for increasing uridine levels with L-nucleosides |
US5700590A (en) * | 1994-01-10 | 1997-12-23 | Abbott Laboratories | Nutritional formula with ribo-nucleotides |
JPH07215879A (ja) * | 1994-02-02 | 1995-08-15 | Otsuka Pharmaceut Factory Inc | 抗ストレス組成物 |
DE9412374U1 (de) * | 1994-08-01 | 1994-09-22 | Rauch-Petz, Gisela G., Dr., 80803 München | Nahrungsergänzungsmittel |
JPH0930976A (ja) * | 1995-07-17 | 1997-02-04 | Otsuka Pharmaceut Factory Inc | 記憶低下改善剤 |
US5843024A (en) * | 1996-05-17 | 1998-12-01 | Breonics, Inc. | Solution and process for resuscitation and preparation of ischemically damaged tissue |
US5962459A (en) * | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
IT1290781B1 (it) * | 1996-05-28 | 1998-12-10 | Polifarma Spa | Agente attivo terapeutico per il trattamento di malattie degenerative neuronali. |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
KR100879559B1 (ko) * | 1999-02-23 | 2009-01-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 미토콘드리아 장애의 치료 또는 예방용 제약조성물 |
JP2001233776A (ja) * | 2000-02-25 | 2001-08-28 | Yamasa Shoyu Co Ltd | 学習・記憶能低下改善剤およびその用途 |
US20030114415A1 (en) * | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
-
1999
- 1999-07-30 WO PCT/US1999/017235 patent/WO2000006174A1/en active IP Right Grant
- 1999-07-30 AT AT07116909T patent/ATE446097T1/de active
- 1999-07-30 ES ES07116909T patent/ES2332669T3/es not_active Expired - Lifetime
- 1999-07-30 CA CA002339008A patent/CA2339008C/en not_active Expired - Lifetime
- 1999-07-30 ES ES09173495.4T patent/ES2476940T3/es not_active Expired - Lifetime
- 1999-07-30 PT PT100756618T patent/PT2329829E/pt unknown
- 1999-07-30 DE DE69937198T patent/DE69937198T2/de not_active Expired - Lifetime
- 1999-07-30 DK DK10075661.8T patent/DK2329829T3/da active
- 1999-07-30 JP JP2000562028A patent/JP2003517437A/ja active Pending
- 1999-07-30 PT PT91734954T patent/PT2145627E/pt unknown
- 1999-07-30 PT PT99937631T patent/PT1140104E/pt unknown
- 1999-07-30 EP EP99937631A patent/EP1140104B1/en not_active Expired - Lifetime
- 1999-07-30 ES ES99937631T patent/ES2294850T3/es not_active Expired - Lifetime
- 1999-07-30 DE DE69941586T patent/DE69941586D1/de not_active Expired - Lifetime
- 1999-07-30 ES ES10075660.0T patent/ES2477568T3/es not_active Expired - Lifetime
- 1999-07-30 EP EP10075660.0A patent/EP2322187B1/en not_active Expired - Lifetime
- 1999-07-30 EP EP07116909A patent/EP1870103B1/en not_active Expired - Lifetime
- 1999-07-30 DK DK07116909T patent/DK1870103T3/da active
- 1999-07-30 EP EP10075661.8A patent/EP2329829B1/en not_active Expired - Lifetime
- 1999-07-30 DK DK10075660.0T patent/DK2322187T3/da active
- 1999-07-30 AT AT99937631T patent/ATE374029T1/de active
- 1999-07-30 PT PT100756600T patent/PT2322187E/pt unknown
- 1999-07-30 US US09/363,748 patent/US6989376B2/en not_active Expired - Lifetime
- 1999-07-30 EP EP09173495.4A patent/EP2145627B1/en not_active Expired - Lifetime
- 1999-07-30 PT PT07116909T patent/PT1870103E/pt unknown
- 1999-07-30 DK DK09173495.4T patent/DK2145627T3/da active
- 1999-07-30 ES ES10075661.8T patent/ES2478044T3/es not_active Expired - Lifetime
- 1999-07-30 DK DK99937631T patent/DK1140104T3/da active
-
2009
- 2009-12-01 CY CY20091101264T patent/CY1110570T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2145627E (pt) | Utilização de uridina em combinação com colina para o tratamento de disfunções de humor e emocionais | |
HUP0004439A3 (en) | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders | |
HUP0103856A2 (hu) | Gyógyszerkészítmény akut rendellenességek kezelésére | |
HUP0100069A2 (hu) | 4(3)-Helyettesített-4(3)-aminometilpirán-, -tiopirán- vagy piperidin-származékok, a vegyületek előállítása és neurológiai rendellenességek kezelésében való alkalmazása | |
EP1034255A4 (en) | GLRAL PRECURSORS WITH RESTRICTED LINES FROM THE CENTRAL NERVOUS SYSTEM | |
EP1471871A4 (en) | TREATMENT OF NEUROLOGICAL DYSFUNCTIONS USING FRUCTOPYRANOSIS SULFAMATES AND ERYTHROPOIETIN | |
ZA965938B (en) | Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system. | |
PL363431A1 (en) | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders | |
HK1041827A1 (en) | Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame. | |
DE69318821D1 (de) | Katheter zur Versorgung des Penis mit Medikamenten | |
HK1053264A1 (en) | Phosphonate analogues of mannose-6-phosphate and their use in the treatment of wounds and fibrotic disorders. | |
IL142220A0 (en) | Method of treating viral hemorrhagic fever | |
EP0592903A3 (en) | Use of Ancrod in the manufacture of medications for the treatment of restenosis. | |
ZA978640B (en) | Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis. | |
AU4789099A (en) | Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents | |
ZA935154B (en) | Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions | |
GB9917346D0 (en) | Medicament for treating premature ejaculation | |
IL137007A0 (en) | Compounds with growth hormone releasing properties | |
IL139303A0 (en) | Treatment of arthritis and other similar conditions | |
CA2197176A1 (en) | Use of selegiline for the treatment of epileptic disorders | |
EP1081159A4 (en) | PURIFIED HUMAN ACTIVIN AND PROCESS FOR PRODUCING THE SAME | |
ZA985818B (en) | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders. | |
ZA973538B (en) | Use of phosphonic acid esters for the treatment of functional disorders of the brain and depression. | |
GB9825969D0 (en) | Agents useful in the treatment of reproductive disorders | |
AU4486797A (en) | Compositions and methods useful for the treatment of neurological and mental disorders |